CHIP Phosphomimetic Substitutions for Protein Quality Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods and compositions that improve and maintain protein quality control (PQC) in cells, particularly to inhibit toxic protein accumulation and treat diseases caused by proteotoxicity, such as those associated with myocardial ischemia/reperfusion and neurological disorders like Alzheimer's and Parkinson's disease.
Innovation Solution
The method involves contacting cells with a nucleic acid sequence encoding a carboxy terminus of heat shock cognate 70 interacting protein (CHIP) with phosphomimetic amino acid substitutions at specific positions or inducing the phosphorylation of serine residues in CHIP, enhancing its activity to inhibit toxic protein accumulation and reduce proteotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CHIP protein activity is increased through phosphomimetic substitutions or phosphorylation induction, then toxic protein accumulation is inhibited and protein quality control is improved, but the complexity of the molecular mechanism increases
Solution Approach 1:
The invention changes the phosphorylation state parameter of CHIP protein by introducing phosphomimetic amino acid substitutions (replacing serine or threonine residues with glutamic acid or aspartic acid) or by inducing phosphorylation through PKG activation. This parameter change mimics the phosphorylated state, enhancing CHIP's E3 ubiquitin ligase activity and improving protein quality control without requiring complex external phosphorylation systems
Solution Approach 2:
The invention creates a copy of the phosphorylated CHIP protein state through phosphomimetic substitutions. Instead of relying on the complex natural phosphorylation pathway involving PKG and multiple kinases, the patent directly introduces amino acid substitutions that replicate the functional effect of phosphorylation, simplifying the approach while achieving the desired enhancement of CHIP activity
2Duration of action of stationary object
If phosphomimetic amino acid substitutions are introduced in CHIP, then CHIP binding affinity and half-life are enhanced, but the difficulty of detecting and measuring the modified protein increases
Solution Approach 1:
The invention uses phospho-specific antibodies as intermediaries to detect and measure the phosphorylated or phosphomimetic CHIP protein. These antibodies specifically recognize the phosphorylated form of CHIP at serine 19 or threonine 20, enabling differentiation between wild-type and modified CHIP proteins in cellular and tissue samples despite the subtle amino acid changes
3Object-affected harmful factors
If CHIP activity is enhanced to reduce proteotoxicity, then protection against myocardial infarction and neurodegenerative diseases is improved, but the use of energy for protein synthesis and modification increases
Solution Approach 1:
The invention performs preliminary action by introducing phosphomimetic amino acid substitutions into CHIP protein before stress conditions occur. This pre-modification ensures that CHIP is already in a high-activity state capable of immediately responding to protein misfolding stress, rather than requiring energy-intensive activation pathways during actual stress events
Solution Approach 2:
The phosphomimetic CHIP protein operates in a constitutively active state, providing continuous protein quality control without requiring external activation signals or energy input for phosphorylation. The modified CHIP autonomously maintains enhanced activity levels, reducing the energy burden on the cell while providing sustained protection against proteotoxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces ischemic proteotoxicity and cytotoxicity by enhancing CHIP's binding affinity and half-life, leading to improved protein quality control and protection against myocardial infarction and neurodegenerative diseases.
Implementation Method 1
the CHIP protein comprises at least one phosphomimetic amino acid substitution at position 19 of SEQ ID NO: 1 or at position 20 of SEQ ID NO: 2
Implementation Method 2
increasing or inducing in the cell phosphorylation of a serine residue at (i) position 19 of a human carboxy terminus of heat shock cognate 70 interacting protein (CHIP)
Data Source
AI summary
The disclosure is directed to methods for inhibiting toxic protein accumulation in cells by modulating the phosphorylation of carboxy terminus of heat shock cognate 70 interacting protein (CHIP), as well as a method for treating a disease caused by proteotoxicity in cells by increasing or inducing the activity of CHIP in a subject.